Inhibitor of heat-shock protein 90 enhances the antitumor effect of DNA vaccine targeting clients of heat-shock protein

Chi Chen Lin, Cheng Fen Tu, Meng Chi Yen, Ming Chuan Chen, Wan Jung Hsieh, Wen Chang Chang, Wen Tsang Chang, Ming Derg Lai

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Geldanamycin (GA), a heat-shock protein (HSP) 90 inhibitor, induces degradation of HSP90 client proteins, which may promote the presentation of degradation peptides with major histocompatibility complex class I on cancer cells. We hypothesized that GA may enhance the efficacy of DNA vaccination, and investigated the therapeutic effect of the combination of GA and a DNA vaccine against HSP90 clients p185neu and Met. The efficacy of various doses of GA combined with an N-terminal neu (N′-neu) DNA vaccine was investigated in a transplanted tumor constitutively overexpressing endogenous p185neu. Low-dose (2.5μg) but not high-dose (10μg) GA enhanced the effect of N′-neu DNA vaccination on the inhibition of murine bladder tumor-2 tumors in syngeneic C3H mice. Anti-p185neu antibody titers were similar among all treated groups. Significantly increased infiltrations of CD8+ T cells and NK cells were observed at tumor sites. GA sensitized tumor cells to the cytotoxic effects of lymphocytes. Depletion of CD8+ T cells eliminated most of the therapeutic efficacy; in contrast, depletion of CD4+ T cells enhanced the therapeutic efficacy. A similar enhancing effect was observed for the combination of GA and a DNA vaccine targeting the Met oncogene. Our results support the use of combination of GA and DNA vaccination against GA-targeted proteins.

Original languageEnglish
Pages (from-to)404-410
Number of pages7
JournalMolecular Therapy
Volume15
Issue number2
DOIs
Publication statusPublished - Feb 2007
Externally publishedYes

Fingerprint

HSP90 Heat-Shock Proteins
DNA Vaccines
Heat-Shock Proteins
Vaccination
Neoplasms
T-Lymphocytes
DNA
geldanamycin
Inbred C3H Mouse
Therapeutic Uses
Major Histocompatibility Complex
Oncogenes
Urinary Bladder Neoplasms
Natural Killer Cells
Anti-Idiotypic Antibodies
Proteins
Lymphocytes
Peptides

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Inhibitor of heat-shock protein 90 enhances the antitumor effect of DNA vaccine targeting clients of heat-shock protein. / Lin, Chi Chen; Tu, Cheng Fen; Yen, Meng Chi; Chen, Ming Chuan; Hsieh, Wan Jung; Chang, Wen Chang; Chang, Wen Tsang; Lai, Ming Derg.

In: Molecular Therapy, Vol. 15, No. 2, 02.2007, p. 404-410.

Research output: Contribution to journalArticle

Lin, Chi Chen ; Tu, Cheng Fen ; Yen, Meng Chi ; Chen, Ming Chuan ; Hsieh, Wan Jung ; Chang, Wen Chang ; Chang, Wen Tsang ; Lai, Ming Derg. / Inhibitor of heat-shock protein 90 enhances the antitumor effect of DNA vaccine targeting clients of heat-shock protein. In: Molecular Therapy. 2007 ; Vol. 15, No. 2. pp. 404-410.
@article{cba84b4cc8334b58a931d9ede48e13c1,
title = "Inhibitor of heat-shock protein 90 enhances the antitumor effect of DNA vaccine targeting clients of heat-shock protein",
abstract = "Geldanamycin (GA), a heat-shock protein (HSP) 90 inhibitor, induces degradation of HSP90 client proteins, which may promote the presentation of degradation peptides with major histocompatibility complex class I on cancer cells. We hypothesized that GA may enhance the efficacy of DNA vaccination, and investigated the therapeutic effect of the combination of GA and a DNA vaccine against HSP90 clients p185neu and Met. The efficacy of various doses of GA combined with an N-terminal neu (N′-neu) DNA vaccine was investigated in a transplanted tumor constitutively overexpressing endogenous p185neu. Low-dose (2.5μg) but not high-dose (10μg) GA enhanced the effect of N′-neu DNA vaccination on the inhibition of murine bladder tumor-2 tumors in syngeneic C3H mice. Anti-p185neu antibody titers were similar among all treated groups. Significantly increased infiltrations of CD8+ T cells and NK cells were observed at tumor sites. GA sensitized tumor cells to the cytotoxic effects of lymphocytes. Depletion of CD8+ T cells eliminated most of the therapeutic efficacy; in contrast, depletion of CD4+ T cells enhanced the therapeutic efficacy. A similar enhancing effect was observed for the combination of GA and a DNA vaccine targeting the Met oncogene. Our results support the use of combination of GA and DNA vaccination against GA-targeted proteins.",
author = "Lin, {Chi Chen} and Tu, {Cheng Fen} and Yen, {Meng Chi} and Chen, {Ming Chuan} and Hsieh, {Wan Jung} and Chang, {Wen Chang} and Chang, {Wen Tsang} and Lai, {Ming Derg}",
year = "2007",
month = "2",
doi = "10.1038/sj.mt.6300014",
language = "English",
volume = "15",
pages = "404--410",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Inhibitor of heat-shock protein 90 enhances the antitumor effect of DNA vaccine targeting clients of heat-shock protein

AU - Lin, Chi Chen

AU - Tu, Cheng Fen

AU - Yen, Meng Chi

AU - Chen, Ming Chuan

AU - Hsieh, Wan Jung

AU - Chang, Wen Chang

AU - Chang, Wen Tsang

AU - Lai, Ming Derg

PY - 2007/2

Y1 - 2007/2

N2 - Geldanamycin (GA), a heat-shock protein (HSP) 90 inhibitor, induces degradation of HSP90 client proteins, which may promote the presentation of degradation peptides with major histocompatibility complex class I on cancer cells. We hypothesized that GA may enhance the efficacy of DNA vaccination, and investigated the therapeutic effect of the combination of GA and a DNA vaccine against HSP90 clients p185neu and Met. The efficacy of various doses of GA combined with an N-terminal neu (N′-neu) DNA vaccine was investigated in a transplanted tumor constitutively overexpressing endogenous p185neu. Low-dose (2.5μg) but not high-dose (10μg) GA enhanced the effect of N′-neu DNA vaccination on the inhibition of murine bladder tumor-2 tumors in syngeneic C3H mice. Anti-p185neu antibody titers were similar among all treated groups. Significantly increased infiltrations of CD8+ T cells and NK cells were observed at tumor sites. GA sensitized tumor cells to the cytotoxic effects of lymphocytes. Depletion of CD8+ T cells eliminated most of the therapeutic efficacy; in contrast, depletion of CD4+ T cells enhanced the therapeutic efficacy. A similar enhancing effect was observed for the combination of GA and a DNA vaccine targeting the Met oncogene. Our results support the use of combination of GA and DNA vaccination against GA-targeted proteins.

AB - Geldanamycin (GA), a heat-shock protein (HSP) 90 inhibitor, induces degradation of HSP90 client proteins, which may promote the presentation of degradation peptides with major histocompatibility complex class I on cancer cells. We hypothesized that GA may enhance the efficacy of DNA vaccination, and investigated the therapeutic effect of the combination of GA and a DNA vaccine against HSP90 clients p185neu and Met. The efficacy of various doses of GA combined with an N-terminal neu (N′-neu) DNA vaccine was investigated in a transplanted tumor constitutively overexpressing endogenous p185neu. Low-dose (2.5μg) but not high-dose (10μg) GA enhanced the effect of N′-neu DNA vaccination on the inhibition of murine bladder tumor-2 tumors in syngeneic C3H mice. Anti-p185neu antibody titers were similar among all treated groups. Significantly increased infiltrations of CD8+ T cells and NK cells were observed at tumor sites. GA sensitized tumor cells to the cytotoxic effects of lymphocytes. Depletion of CD8+ T cells eliminated most of the therapeutic efficacy; in contrast, depletion of CD4+ T cells enhanced the therapeutic efficacy. A similar enhancing effect was observed for the combination of GA and a DNA vaccine targeting the Met oncogene. Our results support the use of combination of GA and DNA vaccination against GA-targeted proteins.

UR - http://www.scopus.com/inward/record.url?scp=33846328749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846328749&partnerID=8YFLogxK

U2 - 10.1038/sj.mt.6300014

DO - 10.1038/sj.mt.6300014

M3 - Article

VL - 15

SP - 404

EP - 410

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 2

ER -